Deal Signed Between Frutarom USA, BLIS K12

October 17, 2008

BLIS Technologies Ltd. (Dunedin, New Zealand), developer of BLIS K12, a probiotic for upper airways infection prevention such as bacterial sore throats, tooth and gum disease and chronic bad breath, announced on October 17 that it had signed a distribution agreement with Frutarom, USA (North Bergen, NJ).

BLIS Technologies Ltd. (Dunedin, New Zealand), developer of BLIS K12, a probiotic for upper airways infection prevention such as bacterial sore throats, tooth and gum disease and chronic bad breath, announced on October 17 that it had signed a distribution agreement with Frutarom, USA (North Bergen, NJ).

Frutarom USA will take reign of all sales and marketing, warehousing and distribution activities in North America, while BLIS Technologies will focus on product development efforts and activities with its research partner, The University of Otago (Dunedin, NZ).

The BLIS K12 advanced probiotic will be unveiled on the Frutarom stand at the Supply Side West show in Las Vegas on Oct 23.

“This is a significant opportunity for us to expand our business around a product with both an exceptional safety profile and excellent record of clinical validation for its effectiveness in preventing many common infections of the upper airways and oral cavity,” said Laurent Leduc, vice president of the health division of Frutarom USA.

“Frutarom is a very proactive company and have already secured orders for BLIS K12, even before the ink was dry…(the merger) represents further expansion of our commercial development for BLIS Technologies and it builds on our existing research relationships with Nestle Nutrition in Switzerland,” said Barry Richardson, chief executive of BLIS Technologies Ltd.

Related Content:

News